{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:35:21Z","timestamp":1791876921578,"version":"4.3.4"},"reference-count":49,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jtct.2025.02.016","type":"journal-article","created":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T11:14:40Z","timestamp":1740222880000},"page":"351.e1-351.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Tisagenlecleucel in Practice: Real-World Lessons in Pediatric and Young Adult B-ALL"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4359-3569","authenticated-orcid":false,"given":"Kevin O.","family":"McNerney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9512-7597","authenticated-orcid":false,"given":"Liora M.","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18 Pt 1","key":"10.1016\/j.jtct.2025.02.016_bib0001","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-07-0674","article-title":"Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts","volume":"13","author":"Brentjens","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"9967","key":"10.1016\/j.jtct.2025.02.016_bib0002","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.jtct.2025.02.016_bib0003","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jtct.2025.02.016_bib0004","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.jtct.2025.02.016_bib0005","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2025.02.016_bib0006","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.20.03585","article-title":"Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor Consortium report","volume":"40","author":"Schultz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.jtct.2025.02.016_bib0007","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jtct.2025.02.016_bib0008","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1182\/bloodadvances.2022007423","article-title":"Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells","volume":"7","author":"Lamble","year":"2022","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.jtct.2025.02.016_bib0009","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1200\/JCO.21.01405","article-title":"Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL","volume":"40","author":"Myers","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2025.02.016_bib0010","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.10016","article-title":"Evolution of tisagenlecleucel use for the treatment of pediatric and young adult relapsed\/refractory (r\/r) B-cell acute lymphoblastic leukemia (B-ALL): Center for International Blood & Marrow Transplant Research (CIBMTR) registry results","author":"Rouce","year":"2024","journal-title":"Am Soc Clin Oncol"},{"key":"10.1016\/j.jtct.2025.02.016_bib0011","unstructured":"Cusatis RLC, Feng Z, Allbee-Johnson M, Shaw BE. Current uses and outcomes of cellular therapies: CIBMTR summary slides. In: CIBMTR, editor; 2023. cibmtr.org\/cibmtr\/resources\/summary-slides-reports. Accessed June 11, 2024."},{"issue":"11","key":"10.1016\/j.jtct.2025.02.016_bib0012","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1182\/bloodadvances.2022008981","article-title":"CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany","volume":"7","author":"Bader","year":"2023","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.jtct.2025.02.016_bib0013","doi-asserted-by":"crossref","first-page":"e766","DOI":"10.1016\/S2352-3026(22)00225-3","article-title":"Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study","volume":"9","author":"Ghorashian","year":"2022","journal-title":"Lancet Haematol"},{"issue":"14","key":"10.1016\/j.jtct.2025.02.016_bib0014","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1182\/bloodadvances.2021006393","article-title":"Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia","volume":"6","author":"Moskop","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jtct.2025.02.016_bib0015","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1182\/bloodadvances.2022007423","article-title":"Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells","volume":"7","author":"Lamble","year":"2023","journal-title":"Blood Adv"},{"issue":"16_suppl","key":"10.1016\/j.jtct.2025.02.016_bib0016","doi-asserted-by":"crossref","first-page":"10016","DOI":"10.1200\/JCO.2022.40.16_suppl.10016","article-title":"Outcomes of Hispanic and non-Hispanic white pediatric and young adult patients with B-cell acute lymphoblastic leukemia after commercial tisagenlecleucel","volume":"40","author":"Vandris","year":"2022","journal-title":"Am Soc Clin Oncol (ASCO)"},{"issue":"17","key":"10.1016\/j.jtct.2025.02.016_bib0017","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1002\/cncr.30089","article-title":"Racial disparities in the survival of American children, adolescents, and young adults with acute lymphoblastic leukemia, acute myelogenous leukemia, and Hodgkin lymphoma","volume":"122","author":"Kahn","year":"2016","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.jtct.2025.02.016_bib0018","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.290.15.2008","article-title":"Survival variability by race and ethnicity in childhood acute lymphoblastic leukemia","volume":"290","author":"Kadan-Lottick","year":"2003","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jtct.2025.02.016_bib0019","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/pbc.21737","article-title":"Outcome and toxicity of chemotherapy for acute lymphoblastic leukemia in children with Down syndrome","volume":"52","author":"Shah","year":"2009","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"10.1016\/j.jtct.2025.02.016_bib0020","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/MPH.0000000000000591","article-title":"Effects of race\/ethnicity and socioeconomic status on outcome in childhood acute lymphoblastic leukemia","volume":"38","author":"Acharya","year":"2016","journal-title":"J Pediatr Hematol\/Oncol"},{"issue":"6","key":"10.1016\/j.jtct.2025.02.016_bib0021","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/s41375-022-01550-z","article-title":"Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed\/refractory acute lymphoblastic leukemia","volume":"36","author":"Laetsch","year":"2022","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.jtct.2025.02.016_bib0022","first-page":"73 e1-e9","article-title":"Impact of high disease burden on survival in pediatric patients with B-ALL treated with Tisagenlecleucel","volume":"28","author":"Ravich","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"10.1016\/j.jtct.2025.02.016_bib0023","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1182\/blood.2022016937","article-title":"How I use risk factors for success or failure of CD19 CAR T cells to guide management of children and AYA with B-cell ALL","volume":"141","author":"Myers","year":"2023","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.jtct.2025.02.016_bib0024","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/blood.2019001641","article-title":"Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL","volume":"134","author":"Curran","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2025.02.016_bib0025","first-page":"579 e1-e10","article-title":"Leukapheresis and Tisagenlecleucel manufacturing outcomes in patients age <3 years with relapsed\/refractory acute lymphoblastic leukemia","volume":"29","author":"Fong","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"14","key":"10.1016\/j.jtct.2025.02.016_bib0026","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood.2021012727","article-title":"Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy","volume":"139","author":"Leahy","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2025.02.016_bib0027","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1182\/bloodadvances.2021005564","article-title":"Tisagenlecleucel outcomes in relapsed\/refractory extramedullary ALL: a pediatric real World CAR Consortium Report","volume":"6","author":"Fabrizio","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.jtct.2025.02.016_bib0028","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/j.jtct.2023.12.142","article-title":"Characterization of extramedullary disease (EMD) response to CD19 targeted chimeric antigen receptor T-cells (CART) in patients with relapsed\/refractory B-cell acute lymphoblastic leukemia (B-ALL): a multi-site, retrospective cohort review","volume":"30","author":"Rankin","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.jtct.2025.02.016_bib0029","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41375-022-01546-9","article-title":"CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study","volume":"36","author":"Jacoby","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2025.02.016_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102268","article-title":"Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns","volume":"65","author":"Barsan","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"6","key":"10.1016\/j.jtct.2025.02.016_bib0031","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.jtct.2025.02.016_bib0032","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1182\/bloodadvances.2021006418","article-title":"Optimal fludarabine lymphodepletion is associated with improved outcomes following CAR T-cell Therapy","volume":"6","author":"Fabrizio","year":"2022","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.jtct.2025.02.016_bib0033","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/bloodadvances.2021006700","article-title":"Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia","volume":"6","author":"Dekker","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jtct.2025.02.016_bib0034","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1182\/bloodadvances.2022007246","article-title":"Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium","volume":"7","author":"Stefanski","year":"2023","journal-title":"Blood Advances"},{"issue":"12","key":"10.1016\/j.jtct.2025.02.016_bib0035","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1182\/bloodadvances.2022008893","article-title":"HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL","volume":"7","author":"McNerney","year":"2023","journal-title":"Blood Adv"},{"issue":"17","key":"10.1016\/j.jtct.2025.02.016_bib0036","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1158\/1078-0432.CCR-22-0822","article-title":"Comprehensive serum proteome profiling of Cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome patients with B-cell ALL receiving CAR T19","volume":"28","author":"Diorio","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.jtct.2025.02.016_bib0037","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatric Blood & Cancer"},{"issue":"6","key":"10.1016\/j.jtct.2025.02.016_bib0038","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"issue":"17","key":"10.1016\/j.jtct.2025.02.016_bib0039","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial","volume":"38","author":"Shah","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.jtct.2025.02.016_bib0040","first-page":"438 e1-e16","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jtct.2025.02.016_bib0041","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2025.02.016_bib0042","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.17662","article-title":"Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy","volume":"194","author":"Hines","year":"2021","journal-title":"Br J Haematol"},{"issue":"24","key":"10.1016\/j.jtct.2025.02.016_bib0043","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood.2021011898","article-title":"Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells","volume":"138","author":"Lichtenstein","year":"2021","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jtct.2025.02.016_bib0044","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"24","key":"10.1016\/j.jtct.2025.02.016_bib0045","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2025.02.016_bib0046","doi-asserted-by":"crossref","first-page":"S219","DOI":"10.1016\/j.jtct.2023.12.285","article-title":"Risk factors for hematotoxicity following Tisagenlecleucel for pediatric B-acute lymphoblastic leukemia","volume":"30","author":"McNerney","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"10.1016\/j.jtct.2025.02.016_bib0047","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1182\/blood.2024025910","article-title":"Development of ALL-Hematotox (ALL-HT): predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia","volume":"145","author":"Nair","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2025.02.016_bib0048","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/2643-3230.BCD-21-0095","article-title":"Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia","volume":"3","author":"Pulsipher","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"10.1016\/j.jtct.2025.02.016_bib0049","first-page":"75 e1-e11","article-title":"Practice preferences for consolidative hematopoietic stem cell transplantation following Tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia","volume":"30","author":"McNerney","year":"2024","journal-title":"Transplant Cell Ther"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725010504?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725010504?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T02:10:49Z","timestamp":1780279849000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725010504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2666636725010504"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.02.016","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tisagenlecleucel in Practice: Real-World Lessons in Pediatric and Young Adult B-ALL","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.02.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}